Department of Pharmaceutics, the 94th Hospital of PLA , Nanchang , China.
Pharm Dev Technol. 2014 May;19(3):363-72. doi: 10.3109/10837450.2013.788517. Epub 2013 May 1.
The objective of this study was to prepare and characterize ursodeoxycholic acid submicron emulsion (UA-SME) loaded with ursodeoxycholic acid phytosomes (UA-PS) and optimize the process variables. A screening experiment with response surface methodology with Box-Behnken design (BBD) was used to optimize the process parameters of UA-SME. The blood concentrations of UA after oral administration of UA-SME and UA coarse drug were assayed. The optimum process conditions were finally obtained by using a desirability function. It was found that stirring velocity, homogenization pressure and homogenization cycles were the most important variables that affected the particles size, polydispersity index and entrapment efficiency of UA-SME. Results showed that the optimum stirring velocity, homogenization pressure and cycles were 16 000 rpm, 60 MPa and 10 cycles, respectively. The mean diameter, polydispersity index and entrapment efficiency of UA-SME were 251.9 nm, 0.241 and 74.36%, respectively. Pharmacokinetic parameters of UA and UA-SME in rats were Tmax 2.215 and 1.489 h, Cmax 0.0364 and 0.1562 μg/mL, AUC0-∞ 3.682 and 13.756 μg h/mL, respectively. The bioavailability of UA in rats was significantly different (p < 0.05) after oral administration of UA-SME compared to those of UA coarse drug. This was due to improvement of the hydrophilicity and lipophilic property of UA-SME.
本研究旨在制备并表征熊去氧胆酸亚微乳(UA-SME)载熊去氧胆酸植物甾醇体(UA-PS),并优化工艺变量。采用 Box-Behnken 设计(BBD)的响应面法筛选实验优化 UA-SME 的工艺参数。测定口服 UA-SME 和 UA 粗药后 UA 的血药浓度。最后通过使用适宜性函数获得最佳工艺条件。结果发现搅拌速度、均质压力和均质循环是影响 UA-SME 粒径、多分散指数和包封效率的最重要变量。结果表明,最佳搅拌速度、均质压力和循环分别为 16000rpm、60MPa 和 10 次。UA-SME 的平均粒径、多分散指数和包封效率分别为 251.9nm、0.241 和 74.36%。大鼠体内 UA 和 UA-SME 的药代动力学参数 Tmax 分别为 2.215 和 1.489h,Cmax 分别为 0.0364 和 0.1562μg/mL,AUC0-∞ 分别为 3.682 和 13.756μg·h/mL。与 UA 粗药相比,大鼠口服 UA-SME 后 UA 的生物利用度有显著差异(p<0.05)。这是由于 UA-SME 的亲水性和疏脂性得到了改善。